LeMaitre Vascular, Inc.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-63.9% vs price
Base Case (Median)
-52.2% vs price
Bull Case (75th pct.)
-23.3% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $19.29 | -77.0% | High (40%) |
| PE Comparable | $63.45 | -24.3% | Medium (25%) |
| Growth Trajectory DCF | $98.12 | 17.0% | Medium (20%) |
| Graham Number | $33.39 | -60.2% | Medium (40%) |
| EV/EBITDA | $40.10 | -52.2% | Medium (20%) |
| EV/FCF | $65.22 | -22.2% | Medium (20%) |
| Earnings Power Value | $27.16 | -67.6% | Medium (50%) |
Based on 7 out of 8 methods, LMAT appears overvalued at the current price of $83.87. The base case fair value of $40.10 implies 52.2% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.